Keeping muscle on GLP-1 drugs

This is a food-and-exercise guide, not a therapeutic peptide profile. During GLP-1-based weight loss, adequate protein and resistance training support preservation of lean tissue and function. No single protein number guarantees muscle preservation. The plan needs to fit appetite, body size, activity, age and kidney health. 2026 musculoskeletal review

An energy deficit changes tissue turnover, while a lighter body needs less tissue to carry and move its weight. Appetite suppression and gastrointestinal symptoms can also make adequate protein and energy harder to obtain. Low loading of muscle adds to the problem. These mechanisms can accompany several forms of weight loss; a lower lean-mass reading alone does not establish direct drug toxicity. Mechanistic review; Musculoskeletal review

Lean mass is not the same measurement as skeletal muscle or strength. DXA and bioimpedance include non-muscle tissue and are affected by body water. Loss of lean tissue can coexist with better mobility and a higher proportion of lean tissue after larger fat loss. Measurement review

The following are nutrition guidance or clinical-trial intake ranges, not medication doses. In obesity, the denominator matters: actual, adjusted/ideal and lean body weight are different. The joint advisory acknowledges that the best basis is uncertain and that actual weight may overestimate requirements. A dietitian can choose a usable target and explain which weight it uses. Joint advisory

For illustration only, applying the advisory's 1.2–1.6 range to a chosen 70-kg reference weight gives 84–112 g/day. This arithmetic does not decide which reference weight is appropriate.

The Longland result does not justify recommending 2.4 g/kg/day to everyone. Separately, a meta-analysis of 49 resistance-training studies in healthy adults found modest added benefits from protein supplementation, with no further average fat-free-mass benefit above about 1.6 g/kg/day in its meta-regression. These studies do not establish the optimum during GLP-1 treatment, particularly in older or medically complex adults. Longland trial; Morton meta-analysis

Protein provides building material; resistance exercise supplies the loading stimulus. Include progressive work for major muscle groups, scaled to current ability. The AHA statement supports muscle-strengthening activity at least two days per week; the GLP-1 joint advisory suggests at least three strength sessions weekly with aerobic activity. These are guidance targets to adapt, not evidence that everyone needs the same programme. AHA statement; GLP-1 advisory

Distribute the chosen daily amount across meals. A resistance-training review proposed around 0.4 g/kg per meal across four meals to reach 1.6 g/kg/day. This is an extrapolation, not a proven GLP-1 meal schedule or a limit on absorption. For a 70-kg reference weight, that illustration is about 28 g at each of four eating occasions. Distribution review

Include protein at breakfast and lunch as well as dinner. Useful options include eggs, fish, poultry, dairy, tofu/soy foods, beans and lentils; use variety within a balanced dietary pattern. Dietary guidelines When appetite is low, smaller meals and a tolerable protein-rich food early in the meal can help. A shake or nutritionally complete supplement can fill a measured gap when food is insufficient; it does not replace the exercise component. Nutrition scoping review; Joint advisory

Kidney disease changes the plan. For non-dialysis adults with CKD G3–G5, KDIGO suggests about 0.8 g/kg/day, and advises avoiding more than 1.3 g/kg/day when progression is a concern. Frailty, undernutrition, acute illness and dialysis require separate assessment; do not apply an ordinary weight-loss protein target automatically. KDIGO, section 3.3.1

Review strength, everyday function, dietary adequacy and symptoms alongside the scale. Persistent vomiting, inability to maintain intake, dehydration or declining strength warrant contact with the treating team and dietitian. A home scale's lean-mass estimate should be interpreted cautiously, especially when hydration changes. Musculoskeletal review

Protein guidance for GLP-1 users still relies partly on studies of calorie restriction and exercise outside drug treatment. Direct trials have not established one optimal intake or meal pattern. The useful objective is adequate nutrition and preserved function throughout treatment, with a plan that can actually be followed. Systematic scoping review